Skip to content

Control efficacy on 24-hour intraocular pressure in primary open-angle glaucoma using selective laser trabeculoplasty versus prostaglandin analogue

Control efficacy on 24-hour intraocular pressure in primary open-angle glaucoma using selective laser trabeculoplasty and prostaglandin analogue

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200056850
Enrollment
Unknown
Registered
2022-02-19
Start date
2019-11-26
Completion date
Unknown
Last updated
2023-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Interventions

Group 1:Selective laser trabeculoplasty
Group 2:Prost derivative eye drops

Sponsors

Eye Hospital, China Acadamy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. No SLT treatment, no prostaglandin derivative eye water for more than 1 month; 2. Patients with primary open-angle glaucoma whose local intraocular pressure cannot reach the target intraocular pressure (determined by evaluating the progression of optic nerve damage according to the visual field, optic disc morphology, and optic nerve fiber layer thickness).

Exclusion criteria

Exclusion criteria: 1. Patients who have undergone eye surgery. 2. Fail to attend the follow-up as required. 3. Patients whose intraocular pressure was still >30mmHg after 1 month of eye water point treatment with SLT or prostaglandin derivatives needed anti-glaucoma surgery. 4. Voluntary withdrawal or loss of follow-up. 5. If the investigator determines that the patient did not comply with trial procedures or for safety reasons, the subject may be withdrawn.

Design outcomes

Primary

MeasureTime frame
Intraocular pressure;

Secondary

MeasureTime frame
Central corneal thickness;Visual field;Optical coherence tomography;

Countries

China

Contacts

Public ContactXie Xiaobin

Eye Hospital, China Acadamy of Chinese Medical Sciences

xiexiaobin0622@163.com+86 13718906796

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026